Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. TREM2 and immune genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

Triggering receptor expressed on myeloid cells 2 (TREM2) plays important roles in brain microglial function in neurodegenerative diseases, but the role of TREM2 in the GBM TME has not been examined. Here, we found that TREM2 is highly expressed in myeloid subsets, including macrophages and microglia in human and mouse GBM tumors and that high TREM2 expression correlates with poor prognosis in patients with GBM. TREM2 loss of function in human macrophages and mouse myeloid cells increased interferon-γ-induced immunoactivation, proinflammatory polarization, and tumoricidal capacity.

What this study adds

Evidence grade: Low

This study is about glioblastoma, not Alzheimer's disease, and found that blocking TREM2 increased antitumor activity of myeloid cells and reduced tumors in mice. It provides no evidence about treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sun, R., Han, R., McCornack, C., Khan, S., Tabor, G. T., Chen, Y., et al. (2023). TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma. Science advances. https://doi.org/10.1126/sciadv.ade3559

Vancouver

Sun R, Han R, McCornack C, Khan S, Tabor GT, Chen Y, et al. TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma. Science advances. 2023. doi:10.1126/sciadv.ade3559. PMID: 37172094.

BibTeX

@article{sun2023-37172094,
  author  = {Sun, R. and Han, R. and McCornack, C. and Khan, S. and Tabor, G. T. and Chen, Y. and Hou, J. and Jiang, H. and others},
  title   = {{TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma}},
  journal = {Science advances},
  year    = {2023},
  doi     = {10.1126/sciadv.ade3559},
  pmid    = {37172094},
  url     = {https://doi.org/10.1126/sciadv.ade3559}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study is about glioblastoma, not Alzheimer's disease, and found that blocking TREM2 increased antitumor activity of myeloid cells and reduced tumors in mice. It provides no evidence about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Science advances)
Journal's citation record 3 / 4 Science Advances: journal h-index 378 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 117 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.4 citations a year over 5 year(s) since 2023
Impact for its field and year 4 / 6 Cited 16.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 3 / 4 Cited 104 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Albert H. Kim: h-index 56 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37172094)
Free to read 2 / 2 Free to read
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in TREM2 and immune genetics from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →